Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
LivaNova PLC is a medical devices business based in the US. LivaNova shares (LIVN) are listed on the NASDAQ and all prices are listed in US Dollars. LivaNova employs 4,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $84.78 |
|---|---|
| 52-week range | $61.76 - $93.89 |
| 50-day moving average | $84.32 |
| 200-day moving average | $82.53 |
| Wall St. target price | $106.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-8.23 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $84.78 from 2022-01-14
| 1 week (2022-01-05) | N/A |
|---|---|
| 1 month (2021-12-16) | 9.68% |
| 3 months (2021-10-15) | 1.06% |
| 6 months (2021-07-16) | 9.11% |
| 1 year (2021-01-15) | 24.48% |
|---|---|
| 2 years (2020-01-16) | 12.80% |
| 3 years (2019-01-16) | 90.11 |
| 5 years (2017-01-13) | 78.94% |
Valuing LivaNova stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LivaNova's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LivaNova's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0239. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LivaNova's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
LivaNova's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $64.3 million.
The EBITDA is a measure of a LivaNova's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1 billion |
|---|---|
| Operating margin TTM | 0.97% |
| Gross profit TTM | $605.3 million |
| Return on assets TTM | 0.27% |
| Return on equity TTM | -30.53% |
| Profit margin | -39.34% |
| Book value | $24.66 |
| Market capitalisation | $4.3 billion |
TTM: trailing 12 months
We're not expecting LivaNova to pay a dividend over the next 12 months.
Over the last 12 months, LivaNova's shares have ranged in value from as little as $61.76 up to $93.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LivaNova's is 0.8936. This would suggest that LivaNova's shares are less volatile than average (for this exchange).
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.